In oncology, targeted agents that inhibit tumor-derived osteolytic cytokines (e.g., IL-6 or PTHrP) and emerging anti-sclerostin antibodies (e.g., romosozumab) further contribute to bone protection [37,38,39]. This evidence concerns the gene IL6 and neoplasm.